Growth rate-corrected (GR) dose-response metric signatures across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 3 of 4: Median, upper quartile, and lower quartile GR metrics per perturbagen. - Dataset (ID:20270)
Small Molecules Studied
Download: Excel (XLSX), Comma-separated (CSV), Images (Zip file)
| HMS LINCS ID | Name | Alternative Names | LINCS ID | Structure Image | PubChem CID |
|---|---|---|---|---|---|
| 10243-1 | CGC-11047 | PG11047 | LSM-4266 |  | 476863 |
| 10242-1 | Carboplatin | LSM-44959 |  | 5237030 | |
| 10241 | Bortezomib | Velcade | LSM-6281 |  | 387447 |
| 10241-4 | Bortezomib | Velcade | LSM-6281 | | 387447 |
| 10241-1 | Bortezomib | Velcade | LSM-6281 | | 387447 |
| 10240-1 | AS-252424 | LSM-4263 |  | 56965900 | |
| 10239-1 | AG1024 | Tyrphostin AG 1024 | LSM-4262 |  | 2044 |
| 10238-1 | 5-FU | Fluorouracil | LSM-4261 |  | 3385 |
| 10237-1 | 5-DFUR | 5-FdUR; Doxifluridine | LSM-6359 |  | 18343 |
| 10236-1 | 17-AAG | Tanespimycin | LSM-43239 |  | 151069 |
| 10235-2 | Everolimus | RAD001 | LSM-4258 |  | 53398658 |
| 10232-2 | Dactolisib | BEZ235; NVP-BEZ235 | LSM-4255 |  | 11977753 |
| 10230-2 | Lestaurtinib | CEP-701 | LSM-1231 |  | 126565 |
| 10228-2 | IKK16 | LSM-2309 |  | 9549298 | |
| 10223-2 | AG1478 | Tyrphostin | LSM-1224 |  | 2051 |
| 10208-2 | JNK-IN-5A | TCS JNK 5a; KIN001-188 | LSM-1209 |  | 766949 |
| 10189-2 | Bosutinib | SKI-606 | LSM-1190 |  | 5328940 |
| 10175-3 | Sunitinib | Sutent; SU11248 | LSM-42800 |  | 3086686 |
| 10146-2 | Omipalisib | GSK2126458; GSK2126458A | LSM-1147 |  | 25167777 |
| 10142-2 | Trametinib | GSK-1120212; GSK1120212; GSK1120212B; JTP-74057 | LSM-1143 |  | 11707110 |
| 10136-2 | TPCA-1 | LSM-1136 |  | 9903786 | |
| 10133-2 | Afatinib | BIBW-2992 | LSM-43226 |  | 57519523 |
| 10110-3 | FR180204 | FR 180204; KIN001-230 | LSM-42790 |  | 11493598 |
| 10108-2 | Geldanamycin | LSM-42789 |  | 644250 | |
| 10107-2 | MG-132 | LSM-1107 |  | 462382 |